Ferric pyrophosphate citrate (Triferic) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients

Nephrology Dialysis Transplantation

Volumn 30, Issue 12, 2015, Pages 2019-2026

  Fishbane, Steven N ^a   Singh, Ajay K ^b   Cournoyer, Serge H ^c   Jindal, Kailash K ^d   Fanti, Paolo ^e   Guss, Carrie D ^f   Lin, Vivian H ^f   Pratt, Raymond D ^f   Gupta, Ajay ^f,g  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HÔPITAL CHARLES LEMOYNE   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f Rockwell Medical Technologies Inc   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anemia; erythropoiesis stimulating agent; ferric pyrophosphate citrate; hemodialysis; iron

Indexed keywords

FERRIC PYROPHOSPHATE; FERRITIN; HEMOGLOBIN; PLACEBO; ANTIANEMIC AGENT; DIALYSIS FLUID; FERRIC CITRATE; FERRIC ION; IRON; PYROPHOSPHORIC ACID DERIVATIVE;

ADULT; ANEMIA; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIALYSATE; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; IRON BALANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANEMIA, IRON-DEFICIENCY; CLINICAL TRIAL; DIETARY SUPPLEMENT; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; DIALYSIS SOLUTIONS; DIETARY SUPPLEMENTS; DIPHOSPHATES; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84954059104     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv277     Document Type: Article

References (13)

1. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23: 1631-1634
2. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004; 22: 112-1123
3. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116: 4754-4761
4. Zumbrennen-Bullough K, Babitt JL. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 2014; 29: 263-273
5. Bailie GR, Larkina M, Goodkin DA et al. Variation in intravenous iron use internationally and over time: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013; 28: 2570-2579
6. Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000
7. Gupta A, Amin NB, Besarab A et al. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int 1999; 55: 1891-1898
8. Gupta A, Crumbliss AL. Treatment of iron deficiency anemia: Are monomeric iron compounds suitable for parenteral administration? J Lab Clin Med 2000; 136: 371-378
9. Huebers HA, Finch CA. The physiology of transferrin and transferrin receptors. Physiol Rev 1987; 67: 520-582
10. Rooyakkers TM, Stroes ES, Kooistra MP et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002; 32 (Suppl 1): 9-16
11. Sengoelge G, Rainer V, Kletzmayr J et al. Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients. Kidney Int 2004; 66: 295-302
12. Oncologic Drugs Advisory Committee, Triferic (ferric pyrophosphate citrex) iron replacement therapy for maintenance of hemoglobin in dialysis patients [Internet]. Wixom (MI): Rockwell Medical, Inc; 2014 Nov 06. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM424049.pdf
13. Bailie GR, Clark JA, Lane CE et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443-1449